Absorb III: A Clinical Evaluation of Absorb™ BVS, the Everolimus
Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects
With de Novo Native Coronary Artery Lesions.
Sponsor: Abbott Vascular
PI: Antonis Pratsos, MD
CRC: Lynn Sher - 484.337.4386
ABSORB III will evaluate the safety and effectiveness of the Absorb BVS
System compared to the XIENCE in the treatment of subjects, including
those with diabetes mellitus, with ischemic heart disease caused by up
to two de novo native coronary artery lesions in separate epicardial
For additional information on cardiovascular clinical
trials, please call Ann Marie Chikowski, BSN, RN, CCRC, Clinical
Research Manager at 484.476.3030.
For more information, call 1.866.CALL.MLH.